Corteva, Inc.
CTVA - NYSE - $83.91 ▲ +%2.72
-
Earnings Tue 5 May
Note: this preview was published before the 2026-05-05 earnings report. Results have since been released — verify against the latest filings.

Corteva opens the
books on Tuesday evening.

5 analysts' median target is $88[FMP target], stock is $84, +4.9% upside potential. After Q4 +-1.3% EPS beat[FMP earnings], the stock moved +0.1%.

↓ summary below
Quick Take - in 40 seconds
B+
HOLD Council 2/6 - Moonshot 36

B+ = MoonshotScore 36[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q1 consensus: revenue $4.6B[FMP est], EPS $1.18[FMP est]. 0 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$1.18 EPS Estimate Last year $1.13 - +4% YoY YoY
0 Beat Streak Expectations beaten consecutively for the last 0 quarters

Q4 EPS +-1.3% beat[FMP] but the stock +0.1% D+1[FMP D+1]. David Johnson promised $81.0M CapEx + a sequential decline in Q1 during the Q4 earnings call[David Johnson capex transcript].

Watchlist

4 metrics stand out this quarter.

7% Investor Focus

2026 EBITDA Growth

2026_EBITDA_Growth

Corteva expects approximately 7% operating EBITDA growth for 2026.

"2026 operating EBITDA is expected to be in the range of $4 billion and $4.2 billion or approximately 7% improvement over prior year at the midpoint."

- David Johnson, Executive Vice President and Chief Financial Officer - Q4 FY25 Earnings Call - February 4, 2026
10 Investor Focus

Bayer Resolution Earnings Upside

Bayer_Resolution_Earnings_Upside

Corteva believes the agreement with Bayer will generate about $1 billion of aggregate earnings upside for Corteva across their corn, cotton, and canola portfolios over the next 10 years.

"However, over the course of the next 10 years, we believe this agreement will generate about $1 billion of aggregate earnings upside for Corteva across our corn, cotton and canola portfolios through both out-licensing and branded sales."

- Charles Magro, Chief Executive Officer - Q4 FY25 Earnings Call - February 4, 2026
2026 Investor Focus

Royalty Neutrality Acceleration

Royalty_Neutrality_Acceleration

Corteva now expects to achieve royalty neutrality in 2026, which is 2 years ahead of their most recent expectations.

"As a result of this resolution and the progress we've been making across the broader out-licensing spectrum, we now expect to achieve royalty neutrality in 2026, which is 2 years ahead of our most recent expectations."

- Charles Magro, Chief Executive Officer - Q4 FY25 Earnings Call - February 4, 2026
60% Investor Focus

H1 2026 Sales EBITDA Concentration

H1_2026_Sales_EBITDA_Concentration

Corteva is expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year.

"Regarding the timing of sales and earnings in 2026, we are expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year."

- David Johnson, Executive Vice President and Chief Financial Officer - Q4 FY25 Earnings Call - February 4, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 36 / 100

9-pillar methodology. R&D Intensity and Price Momentum strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth0.0Q1 vs Q2: growth negative (-24.0%, contraction)
Gross Margin0.0Q1: low margin (0.0%, capital-intensive or commodity)
Operating Leverage1.0op margin average (14.8%)
Cash Runway3.0FCF negative ($-3.0B, external financing needed)
R&D Intensity7.0balanced R&D investment (8.5%)
Price Momentum7.0RSI 64.3 positive momentum, 50d above
News Sentiment7.0majority buy (68%)
Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +4.9%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 64
Klarman value - target upside +4.9%
Buffett quality - ROE score 3/5
Munger valuation - target upside +4.9%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
64.3 RSI 64.3 positive momentum, 50d above
MACD
+4.20 price above 50d - support positive
50d MA
$81 stock 4.2% above - short-term support
200d MA
$72 stock 16.8% above - long-term support
Volume (10d)
+62% increase - pre-earnings positioning
Resistance
$88
Analyst median target - upgrade trigger if broken
Current
$84
Pre-earnings position
Support
$61
Invalidation - close below this is a technical breakdown
Pattern
Range
$61-$88 band - earnings breakout/breakdown trigger

Past Performance

Corteva,'s last 8 quarters: 0 consecutive beats.

BEAT
Q1 FY25
$1.13 vs $0.87 est - +7.0%
BEAT
Q2 FY25
$2.20 vs $1.89 est - -0.2%
BEAT
Q3 FY25
$-0.23 vs $-0.51 est - +1.9%
MISS
Q4 FY25
$0.22 vs $0.22 est - +0.1%

Q4 (February 4, 2026): EPS $0.22 vs $0.22 est[FMP], +-1.3% beat. D+1 movement: +0.1%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $1.14 (no guidance)

Q4: EPS $0.22 vs $0.22 beat[FMP], stock +0.1% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

CapEx shock

Q4 CapEx $81.0M[FMP cashflow]. Q4 op margin 14.8%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q1 EPS > $1.18 + CapEx discipline
Threshold: EPS > $1.18[FMP est].
Target: Break above median target $88[FMP target]; high target $95[FMP] upper bound.
Scenario B - In-Line
EPS approx $1.18 + CapEx < $81.0M
Threshold: EPS approx $1.18[FMP est], Q1 CapEx < $81.0M[FMP].
Target: Consolidation in the band between current $84[FMP] and median $88[FMP].
Scenario C - Miss
EPS < $1.14 or CapEx >= $81.0M
Threshold: EPS < $1.14[FMP estx0.97].
Target: Current $84 below SMA200 $72[FMP], if rejection continues, $61[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 5 analysts say?

Wall Street Consensus
$88
12-month median target price (+4.9% upside potential)
15
BUY
7
HOLD
0
SELL
Risk Management
$61
Invalidation level - critical support threshold
$81 - 50-day MA (above, +4.2%)
$72 - 200-day MA (above, +16.8%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - CTVA Q1 FY26
B+

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q1 EPS threshold $1.18[FMP], CapEx threshold "below $81.0M"[David Johnson]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days CTVA dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

May 5, 2026EARNINGSQ1 FY26 results (after market close) + earnings call
May 6, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Jun 19, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Aug 5, 2026EARNINGSQ2 FY26 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the CTVA earnings preview cover?

This CTVA (CTVA) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in CTVA earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.